Every 10-Q that Dare Bioscience, Inc. (DARE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DARE filings page.
Daré Bioscience, Inc. reports that its women’s health business remains focused on developing and commercializing products across contraception, sexual health, vaginal health and other indications, while shifting more resources toward commercial execution, including Section 503B outsourcing and consumer health channels.
For the six months ended June 30, 2026, total revenue was $340,001, primarily from research and development services and royalty revenue. Operating expenses were $5.7 million, leading to a net loss of $5,982,662, compared with a loss of $8,394,790 in 2025. Operating cash outflow was $12,295,690. Cash and cash equivalents were $12,617,594, all from grant funding, and deferred grant funding liability was $14,954,724. Stockholders’ equity turned to a deficit of $560,100, with an accumulated deficit of $194,671,566. The company discloses substantial doubt about its ability to continue as a going concern within 12 months without additional capital and is pursuing options including equity sales (Lincoln Park equity line and a Regulation A preferred stock and warrant offering) and other financings.
Daré Bioscience reported a Q1 2026 net loss of $3.0 million, improving from a $4.4 million loss a year earlier, on modest revenue of $152,455 from research and development services and royalties. Operating expenses fell significantly as research and development spending declined.
The company ended the quarter with $18.5 million in cash and cash equivalents and working capital of about $0.5 million, but most cash is tied to restricted grant funding. Management states there is substantial doubt about its ability to continue as a going concern over the next 12 months without additional capital.
Daré is pursuing a dual-path strategy in women’s health, combining traditional FDA product development with Section 503B compounding and consumer health offerings. To support operations, it is raising funds through a Regulation A preferred/warrant offering and an equity line with Lincoln Park, while also using royalty financing backed by XACIATO sales.
Daré Bioscience reported Q3 2025 results showing minimal revenue and a narrower quarterly loss. Total revenue was $2,262, driven by royalty revenue, while operating expenses fell to $3.67 million, down from $4.72 million a year ago, reflecting lower research and development spending.
Net loss for the quarter was $3.56 million, improving from a $4.70 million loss in Q3 2024. Cash and cash equivalents were $23.08 million at September 30, 2025, up from $15.70 million at year-end, aided by equity financing. The company sold 4,329,116 shares under its March 2023 ATM for gross proceeds of approximately $18.0 million (about $17.6 million net) and 900,000 shares under its Lincoln Park agreement for roughly $2.0 million in net proceeds.
Liquidity remains a key risk. Management disclosed substantial doubt about the company’s ability to continue as a going concern within 12 months, citing ongoing losses, negative operating cash flow, and uncertainty around timing and magnitude of revenue from its Section 503B compounding and consumer health strategies. As of November 12, 2025, 14,289,229 common shares were outstanding.